Literature DB >> 26633698

Epidemiology of Takayasu's arteritis in Turkey.

Merih Birlik1, Yasin Kücükyavas2, Kenan Aksu3, Dilek Solmaz2, Gercek Can4, Ali Taylan5, Servet Akar6, Ismail Sari2, Gokhan Keser3, Fatos Onen2, Nurullah Akkoc2.   

Abstract

OBJECTIVES: To estimate the prevalence and incidence of Takayasu arteritis (TA) among the residents of the city of Izmir, the third largest metropolis in Turkey.
METHODS: Five tertiary care teaching hospitals, which were the only ones that provided rheumatology specialty care during the study period in the city of Izmir from 2006 through 2010, were invited to take part in the present study. A case search was performed electronically in the information systems of these hospitals using The International Classification of Diseases Tenth Revision (ICD-10) code for Takayasu arteritis (M31.4). The diagnosis was confirmed through chart review by a rheumatologist according to the 1990 American College of Rheumatology (ACR) criteria. Annual prevalence was calculated based on the number of patients that were alive at the end of 2010. Age- and sex-adjusted prevalence rates were standardised according to the 2010 Turkish population, based on 2010 Turkish Census.
RESULTS: A total of 41 patients were confirmed to have TA and also to live within the targeted area. The annual prevalence was estimated as 12.8 (95% CI 12.0-13.6) per million; 23.5/million (95% CI 21.9-25.0) in females and 1.9/million (95% CI 1.5-2.4) in males. The prevalence was higher 8.8/million (95% CI 7.7-10.0) in the population >40 years of age. During the study period, the mean annual incidence of TA was estimated as 1.11/million (95% CI 0.54-1.67).
CONCLUSIONS: The first epidemiologic study of TA in a Turkish population suggests that TA is a relatively common vasculitis in Turkey.

Entities:  

Mesh:

Year:  2015        PMID: 26633698

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Takayasu Arteritis: Recent Developments.

Authors:  Maria L F Zaldivar Villon; Jose A Leon de la Rocha; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2019-07-18       Impact factor: 4.592

2.  Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis.

Authors:  Chunling Wu; Ying Sun; Xiaomeng Cui; Sifan Wu; Lili Ma; Huiyong Chen; Yan Yan; Zongfei Ji; Yun Liu; Jiang Lin; Peng Lv; Rongyi Chen; Pingting Yang; Lindi Jiang
Journal:  Ther Adv Chronic Dis       Date:  2020-11-29       Impact factor: 5.091

3.  Lack of Association of Spontaneous Coronary Artery Dissection With Autoimmune Disease.

Authors:  Vanessa L Kronzer; Alex D Tarabochia; Angie S Lobo Romero; Nicholas Y Tan; Thomas J O'Byrne; Cynthia S Crowson; Tamiel N Turley; Elena Myasoedova; John M Davis; Claire E Raphael; Rajiv Gulati; Sharonne N Hayes; Marysia S Tweet
Journal:  J Am Coll Cardiol       Date:  2020-11-10       Impact factor: 24.094

4.  Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study.

Authors:  Xiaomin Dai; Xiaomeng Cui; Ying Sun; Lili Ma; Lindi Jiang
Journal:  Ther Adv Chronic Dis       Date:  2020-06-05       Impact factor: 5.091

5.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

Review 6.  Takayasu's disease effects on the kidneys: current perspectives.

Authors:  Gioacchino Li Cavoli; Giuseppe Mulè; Mario Giuseppe Vallone; Flavia Caputo
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-08-15

7.  Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study.

Authors:  Sun Ying; Cui Xiaomeng; Dai Xiaomin; Lin Jiang; Lv Peng; Ma Lili; Chen Rongyi; Ji Zongfei; Chen Huiyong; Jiang Lindi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-06-02       Impact factor: 5.346

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.